Evaluation of the effect of two gadolinium-containing contrast-enhancing agents, gadobutrol and gadoxetate disodium, on colorimetric calcium determinations in serum and plasma

Investigative Radiology

Volumn 46, Issue 6, 2011, Pages 366-369

  Löwe, Andrea ^a   Breuer, Josy ^a   Palkowitsch, Petra ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

calcium determination; Contrast enhancement; gadobutrol; gadoxetate disodium; magnetic resonance imaging

Indexed keywords

CALCIUM; ECHOVIST; GADOBUTROL; GADODIAMIDE; GADOVERSETAMIDE; GADOXETIC ACID;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; COLORIMETRY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 79955844647     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318209ed6f     Document Type: Article

References (32)

1. Runge VM, Wells JW. Update: safety, new applications, new MR agents. Top Magn Reson Imaging. 1995;7:181-195.
2. Debatin JF, Hany TF. MR-based assessment of vascular morphology and function. Eur Radiol. 1998;8:528-539. (Pubitemid 128546266)
3. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol. 2003;13:2688-2698. (Pubitemid 37527075)
4. Hentsch A, Aschauer MA, Balzer JO, et al. Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography. Eur Radiol. 2003;13:2103-2114. (Pubitemid 37080744)
5. Schneider G, Uder M. Contrast-enhanced magnetic resonance body imaging 5. Top Magn Reson Imaging. 2003;14:403-425. (Pubitemid 37521731)
6. Löwe A, Balzer T, Hirt U. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol. 2005;40:521-525. (Pubitemid 41040689)
7. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellu-lar carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
8. Ryoo I, Lee JM, Chung YE, et al. Gadobutrol-enhanced, three-dimensional, dynamic MR imaging with MR cholangiography for the preoperative evaluation of bile duct cancer. Invest Radiol. 2010;45:217-224.
9. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest. 1995;55:421-426.
10. Lin J, Idee JM, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using color-imetric reagents. J Pharm Biomed Anal. 1999;21:931-943.
11. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003;227:639-646. (Pubitemid 36583017)
12. Choyke PL, Knopp MV. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology. 2003;227:627-628. (Pubitemid 36583013)
13. Baker JF, Kratz LC, Stevens GR, et al. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pedi-atric subjects. Invest Radiol. 2004;39:334-339. (Pubitemid 38669050)
14. Proctor KA, Rao LV, Roberts WL. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Am J Clin Pathol. 2004;121:282-292. (Pubitemid 38140134)
15. Moore CD, Newman RC, Caridi JG. Spurious hypocalcemia after gadodi-amide-enhanced magnetic resonance imaging: a case report and review of the literature. Rev Urol. 2006;8:165-168.
16. Zhang HL, Ersoy H, Prince MR. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements. J Magn Reson Imaging. 2006;23:383-387. (Pubitemid 43364066)
17. Hayakawa K, Nakamura T, Shimizu Y. Calcium binding by gadolinium-based MR contrast agents. Radiat Med. 2005;23:545-549. (Pubitemid 43151713)
18. Doorenbos CJ, Ozyilmaz A, van Wijnen M. Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. N Engl J Med. 2003; 349:817-818. (Pubitemid 37010794)
19. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576. (Pubitemid 44760175)
20. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582.
21. Bayer HealthCare. Primovist, Summary of Product Characteristics. 2009. Available at: www.medicines.org.uk/EMC/medicine/15927/SPC/Primovist+0. 25+mmol+ml,+solution+for+injection,+prefilled+syringe/#. Accessed July 2009.
22. Bayer HealthCare. Gadovist, Summary of Product Characteristics. 2009. Available at: www.medicines.org.uk/EMC/medicine/9553/SPC/Gadovist+1.0++mmol+ml/ #. Accessed July 2010.
23. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-2352. (Pubitemid 30498114)
24. Tweedle MF. "Stability" of gadolinium chelates. Br J Radiol. 2007;80:583-584.
25. Clarke ET, Martell AE. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles. Inorg Chim Acta. 1999;190:37-46.
26. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for MRI synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). Inorg Chem. 1995;34:633-642.
27. Prince MR, Choyke PL, Knopp MV. More on pseudohypocalcemia and gadolinium-enhanced MRI. N Engl J Med. 2004;350:87-88.
28. Wible JH Jr, Hynes MR. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Radiology. 2004;233:158-164. (Pubitemid 39280970)
29. Kang HP, Scott MG, Joe BN, et al. Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method Clin Chem. 2004;50:741-746.
30. Brown JJ, Hynes MR, Wible JH Jr. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. Am J Roentgenol. 2007;189:1539-1544. (Pubitemid 350174834)
31. Emerson J, Kost G. Spurious hypocalcemia after Omniscan- or Opti-MARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. Arch Pathol Lab Med. 2004;128: 1151-1156. (Pubitemid 39313370)
32. Datta P, Dasgupta A. New method for calcium on the ADVIA analyzer is free from interference of gadolinium-type contrast agents. J Clin Lab Anal. 2009;23:399-403.